二甲双胍治疗奥氮平所致慢性精神分裂症女性患者体质量增加的疗效及安全性分析(1)
【摘要】 目的 探究二甲双胍对奥氮平治疗慢性精神分裂症女性患者体质量及糖脂代谢的影响。方法 64例慢性精神分裂症女性患者， 采用随机数字表法分为观察组和对照组， 每组32例。对照组采用奥氮平进行治疗， 观察组在对照组基础上联合二甲双胍进行治疗。比较两组患者治疗后空腹血糖、甘油三酯、总胆固醇、体质量指数及不良反应发生情况。结果 治疗后， 观察组患者空腹血糖、甘油三酯、总胆固醇和体质量指数分别为(4.55±0.38)mmol/L、(1.33±0.35)mmol/L、(3.52±0.59)mmol/L、(21.88±3.14)kg/m2， 均显著低于对照组的(6.01±0.63)mmol/L、(1.93±0.41)mmol/L、(4.27±0.39)mmol/L、(25.72±3.22)kg/m2， 差异具有统计学意义(P<0.05)。观察组患者不良反应发生率为6.25%， 低于对照组的25.00%， 差异具有统计学意义(P<0.05)。结论 联合二甲双胍可以有效改善奥氮平在慢性精神分裂症女性患者治疗过程中副作用， 改善患者的空腹血糖、甘油三酯、总胆固醇和体质量变化， 并显著降低不良反应发生率， 值得进行临床推广应用。
【關键词】 二甲双胍;奥氮平;慢性精神分裂症;空腹血糖;甘油三酯;总胆固醇;体质量;不良反应
DOI：10.14163/j.cnki.11-5547/r.2020.27.044
Analysis of the effect of metformin on the body mass increase and glucose and lipid metabolism of female patients with chronic schizophrenia treated by olanzapine LI Li-qun， CHEN Wen-lan， LI Lun. Guangzhou Civil Affairs Bureau Mental Hospital， Guangzhou 510000， China
【Abstract】 Objective To investigate the effect of metformin on the body mass and glucose and lipid metabolism of female patients with chronic schizophrenia treated by olanzapine. Methods A total of 64 female patients with chronic schizophrenia were divided into observation group and control group by random numerical table， with 32 cases in each group. The control group was treated with olanzapine， and the observation group was treated with metformin on the basis of the control group. The fasting blood glucose， triglycerides， total cholesterol， body mass index and occurrence of adverse reactions after treatment were compared between the two groups. Results After treatment， the fasting blood glucose， triglycerides， total cholesterol， body mass index of the observation group were (4.55±0.38) mmol/L， (1.33±0.35)mmol/L， (3.52±0.59) mmol/L and (21.88±
3.14) kg/m2， which were significantly lower than those of the control group (6.01±0.63) mmol/L， (1.93±
0.41) mmol/L， (4.27±0.39) mmol/L and (25.72±3.22) kg/m2， and the difference was statistically significant (P<0.05). The incidence of adverse reactions of the observation group was 6.25%， which was lower than that of the control group 25.00%， and the difference was statistically significant (P<0.05). Conclusion Metformin can effectively improve the side effects of olanzapine in the treatment of female patients with chronic schizophrenia， improve fasting blood glucose， triglycerides， total cholesterol and body mass of patients， and significantly reduce the incidence of adverse reactions. It is worthy of clinical promotion and application., 百拇医药(李立群 陈文岚 李论)
【關键词】 二甲双胍;奥氮平;慢性精神分裂症;空腹血糖;甘油三酯;总胆固醇;体质量;不良反应
DOI：10.14163/j.cnki.11-5547/r.2020.27.044
Analysis of the effect of metformin on the body mass increase and glucose and lipid metabolism of female patients with chronic schizophrenia treated by olanzapine LI Li-qun， CHEN Wen-lan， LI Lun. Guangzhou Civil Affairs Bureau Mental Hospital， Guangzhou 510000， China
【Abstract】 Objective To investigate the effect of metformin on the body mass and glucose and lipid metabolism of female patients with chronic schizophrenia treated by olanzapine. Methods A total of 64 female patients with chronic schizophrenia were divided into observation group and control group by random numerical table， with 32 cases in each group. The control group was treated with olanzapine， and the observation group was treated with metformin on the basis of the control group. The fasting blood glucose， triglycerides， total cholesterol， body mass index and occurrence of adverse reactions after treatment were compared between the two groups. Results After treatment， the fasting blood glucose， triglycerides， total cholesterol， body mass index of the observation group were (4.55±0.38) mmol/L， (1.33±0.35)mmol/L， (3.52±0.59) mmol/L and (21.88±
3.14) kg/m2， which were significantly lower than those of the control group (6.01±0.63) mmol/L， (1.93±
0.41) mmol/L， (4.27±0.39) mmol/L and (25.72±3.22) kg/m2， and the difference was statistically significant (P<0.05). The incidence of adverse reactions of the observation group was 6.25%， which was lower than that of the control group 25.00%， and the difference was statistically significant (P<0.05). Conclusion Metformin can effectively improve the side effects of olanzapine in the treatment of female patients with chronic schizophrenia， improve fasting blood glucose， triglycerides， total cholesterol and body mass of patients， and significantly reduce the incidence of adverse reactions. It is worthy of clinical promotion and application., 百拇医药(李立群 陈文岚 李论)